Daniel Liberman

Université de Montréal, Centre Hospitalier de l’Université de Montréal

Papers

Total Citations

H-Index

About

Dr. Daniel Liberman is a leading urologic surgeon and researcher whose work centers on the cost-effectiveness, training, and outcomes of robotic surgery, particularly for prostate cancer. His landmark 2011 study, "Is robotic surgery cost-effective," which has garnered 60 citations, critically assessed the financial burden of robotic technology on healthcare systems, providing essential data for policymakers and surgeons weighing the benefits of robotics against traditional approaches. Dr. Liberman has also advanced surgical education through his work on "Training and outcome monitoring in robotic urologic surgery," emphasizing the need for structured curricula to ensure patient safety. More recently, he contributed to the validation of the novel International Society of Urological Pathology (ISUP) Gleason grading groups, demonstrating their discriminatory power for predicting biochemical recurrence after robot-assisted radical prostatectomy in a large Canadian cohort. With a career dedicated to improving both the economic and clinical outcomes of urologic surgery, Dr. Liberman’s research continues to shape best practices in the field, making him a key figure in the evolution of minimally invasive cancer care.